Literature DB >> 23232505

Value of 11C-methionine PET in imaging brain tumours and metastases.

Andor W J M Glaudemans1, Roelien H Enting, Mart A A M Heesters, Rudi A J O Dierckx, Ronald W J van Rheenen, Annemiek M E Walenkamp, Riemer H J A Slart.   

Abstract

(11)C-methionine (MET) is the most popular amino acid tracer used in PET imaging of brain tumours. Because of its characteristics, MET PET provides a high detection rate of brain tumours and good lesion delineation. This review focuses on the role of MET PET in imaging cerebral gliomas. The Introduction provides a clinical overview of what is important in primary brain tumours, recurrent brain tumours and brain metastases. The indications for radiotherapy and the results and problems arising after chemoradiotherapy in relation to imaging (pseudoprogression or radionecrosis) are discussed. The working mechanism, scan interpretation and quantification possibilities of MET PET are then explained. A literature overview is given of the role of MET PET in primary gliomas (diagnostic accuracy, grading, prognosis, assessment of tumour extent, biopsy and radiotherapy planning), in brain metastases, and in the differentiation between tumour recurrence and radiation necrosis. Finally, MET PET is compared to other nuclear imaging possibilities in brain tumour imaging.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23232505     DOI: 10.1007/s00259-012-2295-5

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  151 in total

1.  Positron emission tomography (11)C-methionine and survival in patients with low-grade gliomas.

Authors:  D Ribom; A Eriksson; M Hartman; H Engler; A Nilsson; B Långström; H Bolander; M Bergström; A Smits
Journal:  Cancer       Date:  2001-09-15       Impact factor: 6.860

Review 2.  MR imaging of cerebral tumors: state of the art and work in progress.

Authors:  H P Higer; P Pedrosa; M Schuth
Journal:  Neurosurg Rev       Date:  1989       Impact factor: 3.042

3.  Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology.

Authors:  Lutz W Kracht; Hrvoje Miletic; Susanne Busch; Andreas H Jacobs; Jurgen Voges; Moritz Hoevels; Johannes C Klein; Karl Herholz; Wolf-D Heiss
Journal:  Clin Cancer Res       Date:  2004-11-01       Impact factor: 12.531

4.  Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies.

Authors:  Benoit Pirotte; Serge Goldman; Nicolas Massager; Philippe David; David Wikler; Maurice Lipszyc; Isabelle Salmon; Jacques Brotchi; Marc Levivier
Journal:  J Neurosurg       Date:  2004-09       Impact factor: 5.115

5.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.

Authors:  Roger Stupp; Monika E Hegi; Warren P Mason; Martin J van den Bent; Martin J B Taphoorn; Robert C Janzer; Samuel K Ludwin; Anouk Allgeier; Barbara Fisher; Karl Belanger; Peter Hau; Alba A Brandes; Johanna Gijtenbeek; Christine Marosi; Charles J Vecht; Karima Mokhtari; Pieter Wesseling; Salvador Villa; Elizabeth Eisenhauer; Thierry Gorlia; Michael Weller; Denis Lacombe; J Gregory Cairncross; René-Olivier Mirimanoff
Journal:  Lancet Oncol       Date:  2009-03-09       Impact factor: 41.316

6.  Synthesis of L- and D-[methyl-11C]methionine.

Authors:  B Långström; G Antoni; P Gullberg; C Halldin; P Malmborg; K Någren; A Rimland; H Svärd
Journal:  J Nucl Med       Date:  1987-06       Impact factor: 10.057

7.  Hypofractionated radiotherapy for poor prognosis malignant glioma: matched pair survival analysis with MRC controls.

Authors:  J J McAleese; S P Stenning; S Ashley; D Traish; F Hines; S Sardell; D Guerrero; Michael Brada
Journal:  Radiother Oncol       Date:  2003-05       Impact factor: 6.280

8.  Positron emission tomography and computed tomography in differential diagnosis between recurrent or residual glioma and treatment-induced brain lesions.

Authors:  A Lilja; H Lundqvist; Y Olsson; B Spännare; P Gullberg; B Långström
Journal:  Acta Radiol       Date:  1989 Mar-Apr       Impact factor: 1.990

9.  Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas.

Authors:  Benoit Pirotte; Serge Goldman; Nicolas Massager; Philippe David; David Wikler; Arlette Vandesteene; Isabelle Salmon; Jacques Brotchi; Marc Levivier
Journal:  J Nucl Med       Date:  2004-08       Impact factor: 10.057

10.  Biomarkers classification and therapeutic decision-making for malignant gliomas.

Authors:  Adriana Olar; Kenneth D Aldape
Journal:  Curr Treat Options Oncol       Date:  2012-12
View more
  90 in total

Review 1.  Fluorine-18 patents (2009-2015). Part 1: novel radiotracers.

Authors:  Allen F Brooks; Lindsey R Drake; Megan N Stewart; Brian P Cary; Isaac M Jackson; Dale Mallette; Andrew V Mossine; Peter J H Scott
Journal:  Pharm Pat Anal       Date:  2015-12-16

2.  Early static (18)F-FET-PET scans have a higher accuracy for glioma grading than the standard 20-40 min scans.

Authors:  Nathalie L Albert; Isabel Winkelmann; Bogdana Suchorska; Vera Wenter; Christine Schmid-Tannwald; Erik Mille; Andrei Todica; Matthias Brendel; Jörg-Christian Tonn; Peter Bartenstein; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-15       Impact factor: 9.236

Review 3.  Non-invasive metabolic imaging of brain tumours in the era of precision medicine.

Authors:  Michelle M Kim; Abhijit Parolia; Mark P Dunphy; Sriram Venneti
Journal:  Nat Rev Clin Oncol       Date:  2016-07-19       Impact factor: 66.675

Review 4.  FDG-PET Contributions to the Pathophysiology of Memory Impairment.

Authors:  Shailendra Segobin; Renaud La Joie; Ludivine Ritz; Hélène Beaunieux; Béatrice Desgranges; Gaël Chételat; Anne Lise Pitel; Francis Eustache
Journal:  Neuropsychol Rev       Date:  2015-08-30       Impact factor: 7.444

Review 5.  Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas.

Authors:  Nathalie L Albert; Michael Weller; Bogdana Suchorska; Norbert Galldiks; Riccardo Soffietti; Michelle M Kim; Christian la Fougère; Whitney Pope; Ian Law; Javier Arbizu; Marc C Chamberlain; Michael Vogelbaum; Ben M Ellingson; Joerg C Tonn
Journal:  Neuro Oncol       Date:  2016-04-21       Impact factor: 12.300

Review 6.  Imaging findings in radiation therapy complications of the central nervous system.

Authors:  Tomonori Kanda; Yuichi Wakabayashi; Feibi Zeng; Yoshiko Ueno; Keitaro Sofue; Takaki Maeda; Munenobu Nogami; Takamichi Murakami
Journal:  Jpn J Radiol       Date:  2018-07-24       Impact factor: 2.374

Review 7.  The wayward methyl group and the cascade to cancer.

Authors:  Robert M Hoffman
Journal:  Cell Cycle       Date:  2017-03-20       Impact factor: 4.534

Review 8.  11C-methionine PET/CT findings in benign brain disease.

Authors:  Reiko Nakajima; Ken Kimura; Koichiro Abe; Shuji Sakai
Journal:  Jpn J Radiol       Date:  2017-04-18       Impact factor: 2.374

9.  Usefulness of ¹¹C-methionine positron emission tomography for treatment-decision making in cases of non-enhancing glioma-like brain lesions.

Authors:  Atsushi Watanabe; Yoshihiro Muragaki; Takashi Maruyama; Jun Shinoda; Yoshikazu Okada
Journal:  J Neurooncol       Date:  2015-11-26       Impact factor: 4.130

10.  The clinical safety, biodistribution and internal radiation dosimetry of [¹⁸F]fluciclovine in healthy adult volunteers.

Authors:  Brian J McParland; Anders Wall; Silvia Johansson; Jens Sørensen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-04-24       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.